Position Statement Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group Cardiometabolic Risk Working Group: Executive Committee: Lawrence A. Leiter (Chair), MD, FRCPC, FACP, a,b David H. Fitchett, MD, FRCPC, a,b Richard E. Gilbert, MD, PhD, FRCPC, FRACP, a,b Milan Gupta, MD, FRCPC, a,b,c,d G. B. John Mancini, MD, FRCPC, FACC, e Philip A. McFarlane, MD, PhD, FRCPC, a,b Robert Ross, PhD, f Hwee Teoh, PhD, a Subodh Verma, MD, PhD, FRCSC, FAHA, a,b Working Group: Sonia Anand, MD, PhD, FRCPC, d Kathryn Camelon, RD, CDE, g Chi-Ming Chow, MDCM, MSc, FRCPC, FACC, a,b Jafna L. Cox, BA, MD, FRCPC, FACC, h Jean-Pierre Després, PhD, FAHA, i Jacques Genest, MD, FRCPC, j Stewart B. Harris, MD, MPH, FCFP, FACPM, k David C. W. Lau, MD, PhD, FRCPC, l Richard Lewanczuk, MD, PhD, m Peter P. Liu, MD, MSc, FRCPC, b,e Eva M. Lonn, MD, MSc, FRCPC, FACC, e Ruth McPherson, MD, PhD, FRCPC, n Paul Poirier, MD, PhD, FRCPC, FACC, FAHA, h Shafiq Qaadri, MD, MPP, o Rémi Rabasa-Lhoret, MD, PhD, p Simon W. Rabkin, MD, FRCPC, FACC, e Arya M. Sharma, MD, PhD, FRCPC, m Andrew W. Steele, MD, FRCPC, q James A. Stone, MD, PhD, FRCPC, FAACVPR, FACC, l Jean-Claude Tardif, MD, FRCPC, FACC, r Sheldon Tobe, MD, FRCPC, b,s Ehud Ur, MB, FRCP e a From the Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada; b University of Toronto, Toronto, Ontario, Canada; c Brampton Civic Hospital, Brampton, Ontario, Canada; d McMaster University, Hamilton, Ontario, Canada; e University of British Columbia, Vancouver, British Columbia, Canada; f Queen’s University, Kingston, Ontario, Canada; g University Health Network, Toronto, Ontario, Canada; h Dalhousie University, Halifax, Nova Scotia, Canada; i Université Laval, Québec City, Québec, Canada; j McGill University, Montreal, Québec, Canada; k University of Western Ontario, London, Ontario, Canada; l University of Calgary, Calgary, Alberta, Canada; m University of Alberta, Edmonton, Alberta, Canada; n University of Ottawa, Ottawa, Ontario, Canada o Etobicoke, Ontario, Canada; p Institut de Recherches Cliniques de Montréal, Montreal, Québec, Canada; q Lakeridge Health Corporation, Oshawa, Ontario, Canada; r Université de Montréal, Montreal, Québec, Canada; s Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada ABSTRACT The concepts of “cardiometabolic risk,” “metabolic syndrome,” and “risk stratification” overlap and relate to the atherogenic process and development of type 2 diabetes. There is confusion about what these terms mean and how they can best be used to improve our under- standing of cardiovascular disease treatment and prevention. With the RÉSUMÉ Les concepts de « risque cardiométabolique », de « syndrome métabolique » et de « stratification du risque » s’entrecoupent et s’apparentent au processus et au développement de l’athérogénèse du diabète de type 2. Il y a confusion sur ce que ces termes signifient et sur la manière de mieux les utiliser pour améliorer notre compréhension du traitement et de la Received for publication September 17, 2010. Accepted October 5, 2010. Corresponding author: Dr Lawrence A. Leiter, Division of Endocrinol- ogy & Metabolism, St Michael’s Hospital, 61 Queen Street East #6121, Toronto, Ontario M5C 2T2, Canada. Tel.: +1-416-867-7441; fax: +1- 416-867-3696. E-mail: LeiterL@smh.ca See page e24 for disclosure information. Canadian Journal of Cardiology 27 (2011) e1– e33 0828-282X/$ – see front matter © 2011 Elsevier Inc. All rights reserved. doi:10.1016/j.cjca.2010.12.054